Turning Point Therapeutics
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of investigational drugs designed to address key limitations of existing cancer therapies. Its lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. The company’s current pipeline of drug candidates also includes elzovantinib, targeting MET, CSF1R and SRC; TPX-0046, targeting RET; and TPX-0131, a next-generation ALK inhibitor. To learn more, visit www.tptherapeutics.com.
Additional Info
Will your company display a new product or promote a new indication/enhanced feature(s) for an existing product in your booth?
No